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Background. Human noroviruses (HuNoVs) are a prominent cause of gastroenteritis, yet fundamental questions remain regard-
ing epidemiology, diversity, and immunity in sub-Saharan African children. We investigated HuNoV seroprevalence and genetic and 
sociodemographic risk factors in Ugandan children.
Methods. We randomly screened 797 participants of a longitudinal birth cohort (Entebbe, EMaBS) and 378 from a cross-sec-
tional survey (rural Lake Victoria, LaVIISWA), for antibodies against HuNoV genotypes by ELISA. We used linear regression mod-
eling to test for associations between HuNoV antibody levels and sociodemographic factors, and with the human susceptibility 
rs601338 FUT2 secretor SNP and histo-blood group antigens (A/B/O).
Results. Of EMaBS participants, 76.6% were seropositive by age 1, rising to 94.5% by age 2 years. Seroprevalence in 1 year olds 
of the rural LaVIISWA survey was even higher (95%). In the birth cohort, 99% of seropositive 2 year olds had responses to multiple 
HuNoV genotypes. We identified associations between secretor status and genogroup GII antibody levels (GII.4 P = 3.1 × 10−52), as 
well as ABO and GI (GI.2 P = 2.1 × 10−12).
Conclusions. HuNoVs are highly prevalent in Ugandan children, indicating a substantial burden of diarrhea-associated mor-
bidity with recurrent infections. Public health interventions, including vaccination, and increased surveillance are urgently needed.
Keywords. norovirus; seroepidemiology; Uganda; histo-blood group antigens. 
Gastroenteritis remains the second leading cause of infection-re-
lated deaths in children under 5  years old globally; sub-Saha-
ran Africa bears the greatest burden [1]. Human noroviruses 
(HuNoVs) are a leading cause of viral gastroenteritis across all 
age groups; however, information regarding their impact and 
epidemiology in African children is extremely limited [2, 3].
The Norovirus genus of positive-strand RNA viruses is 
divided into 7 proposed genogroups (GI–GVII), each subdi-
vided into genotypes, on the basis of the major capsid pro-
tein and polymerase sequences. Strains within genotype GII.4 
have been responsible for the majority of outbreaks since 
1996, with new pandemic variants emerging every few years, 
although greater diversity has been reported in some low-in-
come settings [4].
In low- and middle-income countries, HuNoVs are respon-
sible for >200 000 deaths/year in children <5  years old [5], 
although this is likely to be an underestimate given the lack of 
surveillance in most low-resource countries. Recent studies, 
including 2 pioneering multicenter surveys of childhood diar-
rheal diseases, have begun to address the gaps in knowledge of 
pediatric HuNoV infections in low- and middle-income coun-
tries [6–9]. The geographical distribution of data from these 
and other studies highlights the paucity of information on 
HuNoV prevalence in sub-Saharan Africa [8–10]. The major-
ity of studies of HuNoV in Africa have focused on incidence 
reporting in diarrhea cases for small cohorts using reverse tran-
scription polymerase chain reaction (RT-PCR) based methods. 
Serological data can complement incidence reporting to pro-
vide an overall picture of infections in a particular population. 
The last study of HuNoV seroprevalence from an African coun-
try was published in 1999 [11]; since then the global prevalence 
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of HuNoV is thought to have increased due to the emergence of 
pandemic strains belonging to the GII.4 genotype.
Susceptibility to HuNoV-induced diarrhea is at least partially 
governed by expression of histo-blood group antigens (HBGAs) 
in the gastrointestinal tract, which serve as viral attachment fac-
tors [12]. Intestinal HBGA expression is controlled by the α(1,2) 
fucosyltransferase 2 (FUT2) enzyme. Individuals homozygous 
for a FUT2 nonsense mutation (G428A) are termed “nonsecre-
tors” (Se−) and have been shown to be less susceptible to infec-
tion by certain genotypes of HuNoV, although the relationship 
is complex [13]. There has not yet been a large-scale extensive 
investigation of the association between HBGA status and 
HuNoV infections in an African population.
Recent breakthroughs in the development of long-sought 
systems for HuNoV in vitro cultivation [14, 15], mean that 
targeted antivirals and a multivalent vaccine for HuNoVs are 
within reach, with a vaccine currently advancing in phase 2b 
clinical trials [16]. Understanding HuNoV prevalence and nat-
ural immunity in children in sub-Saharan Africa, where any 
future vaccine could have the greatest impact, is therefore essen-
tial. To address this, we investigated the seroprevalence, age of 
seroconversion, genotype diversity, and genetic and social risk 
factors for HuNoVs among 2 cohorts of Ugandan children.
METHODS
Ethical Approval
This study was approved by the Research and Ethics Committee 
Uganda Virus Research Institute, Uganda National Council for 
Science and Technology, and London School of Hygiene and 
Tropical Medicine Research and Ethics Committee.
Study Populations
The Entebbe Mother and Baby Study (EMaBS) 
(ISRCTN32849447, http://emabs.lshtm.ac.uk/) is a birth cohort 
that originated as a trial of anthelminthics [17]. In total, 2507 
pregnant women in their third trimester were enrolled between 
2003 and 2005. Blood samples collected from the children 
every year after birth (between 2004 and 2011) with informed 
parental consent. The study catchment area was comprised 
periurban, fishing, and rural communities around Entebbe and 
Lake Victoria. From this cohort, 797 children were randomly 
selected for this study. The Lake Victoria Island Intervention 
Study on Worms and Allergy-related diseases (LaVIISWA), 
included a baseline survey performed in 2012–2013 among 
26 island fishing communities in Koome subcounty, Mukono 
District, Uganda [18]. All available samples from 1–5 year olds 
in the LaVIISWA baseline survey were studied.
Virus-Like Particle Preparation
Virus-like particles (VLPs), which are structurally and antigen-
ically indistinguishable from native virions, were generated for 
each strain as previously published [19]. Strains from different 
genotypes, some associated with pediatric infections [20, 21], 
were selected to represent a diverse range that would detect 
responses to recent and older strains. As the genotype GII.4 dis-
plays the greatest antigenic variability and rates of evolution [22, 
23], we selected a GII.4 strain that was identified prior to the 
study sampling dates (Hu/GII.4/FRA/Dijon/1996/Dijon171, 
AF472623). Non-GII.4 genotypes are more antigenically static 
[21, 23] and the following strains were selected: GI.1 (Hu/
NV/I/Norwalk/68/US, GenBank accession no. AAA59229), 
GI.2 (Hu/GI.2/FRA/Dijon/2008/E2818, GenBank accession 
no. KP064095), GII.3 (Hu/GII.3/ FRA/Dijon/2008/E2419, 
GenBank accession no. KP064097), GII.6 (Hu/GII.6/FRA/
Dijon/2011/E5915, GenBank accession no. KP064098), and 
GII.12 (Hu/GII.12/FRA/Dijon/2010/E5152, GenBank acces-
sion no. KP064099).
ELISA for HuNoV IgG Levels
To determine IgG responses to a pool of HuNoV VLPs, enzyme-
linked immunosorbent assays (ELISAs) were performed as 
previously reported [19] (Supplementary Methods). For the 
EMaBS cohort, we began by screening plasma samples from 
children aged 1  year; any that tested negative were then fol-
lowed up at each subsequent age group until a positive response 
was detected. We estimated the cumulative seroprevalence for 
each year group, making the assumption that the missing sam-
ples seroconverted at the same rate as the rest of the age group 
(Supplementary Methods). To screen for individual genotype 
responses, we randomly selected another 800 seropositive sam-
ples from 2-year-old children.
Statistical Analysis
To estimate the cumulative seroprevalence in the EMaBS cohort 
(Supplementary Table 2) for ages 2 years and onwards; we made 
the assumption that children whose samples were not available 
at follow-up ages would have seroconverted at the same rate as 
the ones for whom samples were available in that age group. 
Therefore we calculated the rate of seroconversion for each age 
group (as number seropositive/number available to screen) and 
multiplied it by the total number that should have been screened 
for that age group (the number that had tested seronegative at 
the previous age) to give the estimated positive number. This 
value was added to the estimated positive values of each previ-
ous year and expressed as a percentage out of the total number 
of children included in the study (n = 797). HuNoV seroprev-
alence and 95% confidence intervals for the LaVIISWA survey 
were obtained using “svy” commands in Stata.
 Linear regression modeling of risk factors was performed 
using Stata-13 software (Stata 13.0, Statacorp, College Station). 
For both EMaBS and LaVIISWA, IgG levels (OD450 values) 
to HuNoV were log10 transformed to become approximately 
normally distributed. For EMaBS, linear regression with 
bootstrapped confidence intervals was used to determine the 
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association between HuNoV antibodies and various risk fac-
tors: sex, geographical location, mother’s occupation, house-
hold socioeconomic status (hhSES), human immunodeficiency 
virus (HIV) exposure status, and diarrhea events. Mother’s 
occupation was categorized into 3 groups based on relatedness 
of occupation. Group  1 included farming/fishing, unskilled 
manual labor, and bar/hotel attendants; group 2 included 
housewives; while group 3 included business, students, and pro-
fessionals. A composite value was obtained for hhSES derived 
from the home building materials, number of rooms, and items 
collectively owned at the mother’s home, using principal com-
ponent analysis. Geographical location was categorized into 3 
groups: urban (Entebbe), periurban (Kingungu and Manyago), 
and rural (Katabi). The mother’s HIV status was used to group 
children as either exposed or unexposed, as the number of chil-
dren that tested positive for HIV at 1 year was very low (7/773). 
For mother’s occupation and geographical location, the groups 
were analyzed as nominal variables after testing for departure 
from linear trend. In the crude analysis we reported the P value 
from the Wald test and in the adjusted analysis we reported the 
P value from the likelihood ratio test.
For LaVIISWA, linear regression analyses employed the “svy” 
survey commands in Stata to allow for clustering of respondents 
within villages using linearized standard errors and for variable 
village sizes using weights. Exposures considered were sex, age, 
and child’s school status. Because the outcome variable (IgG 
antibody levels to HuNoV) was log transformed prior to lin-
ear regression modeling, geometric mean ratios were derived 
by back-transforming regression coefficients and their corre-
sponding 95% confidence intervals (CI). During univariate 
analysis, each risk factor was analyzed separately with the out-
come variable for each study. A  linear trend assumption was 
made and tested using the likelihood ratio test when analyzing 
age and hhSES, mother’s occupation, and geographical location. 
During multivariate analysis all risk factors were analyzed with 
the outcome variable using 1 model for each study.
Associations between secretor status and ABO phenotypic 
blood group were assessed using the Student t test implemented 
in R.  Differences in log-transformed distributions of geno-
type-specific antibody levels were tested between 2 groups and 
the final P value reported for each comparison. To test for evi-
dence of interaction between ABO and FUT2 loci, the likeli-
hood of an interaction model was compared to the likelihood of 
a multivariable model (with no interaction) including secretor 
status (Se+ or Se−) and blood group (O or B), using the likeli-
hood ratio test. Sensitivity analyses were performed to ensure 
that the statistics generated from the genetic association analy-
ses were not false positives originating from population stratifi-
cation (Supplementary Methods). Associations between genetic 
variants and diarrhea incidence were assessed using Cox regres-
sion with robust standard errors to allow for the fact that some 
children experienced multiple diarrhea episodes.
Genotype Data for Determining FUT2 Secretor Status and ABO Blood Type
Whole-genome genotype data were available for 651/797 
selected children from EMaBS generated on the Illumina 
Omni2.5M array and quality controlled using standard pipe-
lines, including removing individuals and variants with high 
levels of missingness or deviations from expected levels of het-
erozygosity or Hardy-Weinberg equilibrium. Untyped genetic 
variants, including the FUT2 secretor status SNP (rs601338 at 
position 49 206 674 on chromosome 19 in genome build 37) and 
ABO SNPs (rs8176747 position 136 131 315 and rs8176719 
position 136 132 908 on chromosome 9)  were imputed using 
a merged 1000 Genomes and African-specific reference panel 
[24] using SHAPEIT2 [25] and IMPUTE2 [26] with default 
settings applicable for African populations, and all imputed 
variants were filtered using an info score threshold of 0.3 and 
a minor allele frequency of 0.01 or greater. Imputed dosages of 
secretor A alleles were used to determine secretor status. Se sta-
tus was confirmed by PCR amplification and Sanger sequenc-
ing of the rs601338 SNP at position 49 206 674 on chromosome 
19 for 80 randomly selected EMaBS participants. For ABO, we 
used phased genotypes to determine genetic blood groups using 
Supplementary Table 1 (adapted from [27]). The corresponding 
phenotypic blood groups used for downstream analyses were 
determined using these genetic blood groups.
RESULTS
In participants of the EMaBS longitudinal birth cohort 
(Figure 1A) seroprevalence to the pool of HuNoV was 76.6% 
(611/797) by age 1 year, and 94.5%, 95.2%, 96.1%, and 96.6% at 
2, 3, 4, and 5 years, respectively (Figure 1B and Supplementary 
Table  2). Of the sociodemographic variables considered, resi-
dence in a rural location (within the EMaBS catchment area) 
was the only factor significantly associated with having higher 
antibody levels at age 1 (P = .006; Table 1).
To corroborate the high seroprevalence in the EMaBS cohort 
and investigate whether it differed in more rural geographical 
locations, we used a cross-sectional survey (LaVIISWA) con-
ducted in remote island-shore fishing villages in Lake Victoria, 
only accessible from the mainland in 3 hours by powered canoe 
(Figure  1A) [18]. Seropositivity to the pool of HuNoVs was 
higher in 1 year olds in the LaVIISWA survey (94.7%) than in 
the EMaBS cohort, but was comparable from age 2 onwards 
(Figure 1B and Supplementary Table 3). Age was the only factor 
significantly associated with increased antibody levels in this 
survey (P  <  .0001; Table  2). For every 1-year increase in age, 
we observed an approximately 5% increase in OD450 readings, 
suggesting an increase in HuNoV antibody levels that is most 
likely due to repeat infections (Table 2).
To gain insight into the diversity of HuNoVs circulating in 
Ugandan children, we determined specific genotype seropreva-
lence in 2 year olds from the EMaBS cohort. The seroprevalence 
of the GII.4 virus was comparable to the genotype GI.1 virus 
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at 92.1% and 92.6% respectively (Figure  2A), higher than for 
all other genotypes (Figure  3). All combinations of genotype 
responses were observed for different individuals (Figure 3A). 
Overall, the genotype GII.12 virus had the lowest seropreva-
lence at 69.4% (Figure 2A). In total, 99.1% of seropositive 2 year 
olds displayed multiple genotype-specific serological responses.
As susceptibility to HuNoV-induced diarrhea is at least par-
tially governed by FUT2 secretor (Se) status and gastrointesti-
nal HBGA expression [13], we investigated whether there were 
associations between levels of genotype-specific antibody and 
Se− or ABO type in the EMaBS population. Of the 651 EMaBS 
participants for whom whole-genome genotype data were avail-
able, 23.0% (150/651) were Se− (homozygous for the G428A 
mutation), in line with the frequency previously reported for 
populations with African ancestry [28]. PCR amplification and 
Sanger sequencing confirmed the accuracy of secretor status 
imputation in 80 individuals selected at random. Se− individ-
uals exhibited significantly lower antibody levels against all 
genotypes except GI.1 (Figure  2B), and the effect was most 
prominent for GII genotypes, especially GII.4 (geometric mean 
ratio 1.54 (95% CI, 1.49–1.59); P = 3.12 × 10−52). In contrast, 
an effect was only observed at the ABO locus for GI genotypes, 
GI.2 in particular (Pomnibus  =  2.1  ×  10−12). Given the strong 
concurrent associations at the ABO and FUT2 loci for GI.2 
and the known mechanisms of HBGA expression involving 
FUT2, we expected to see evidence of epistasis between these 
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Figure 1. Human norovirus (HuNoV) seroprevalence in Ugandan children between 1 and 5 years old. A, Study catchment areas for the longitudinal birth cohort around 
Entebbe (Entebbe Mother and Baby Study [EMaBS], shown in red) and a cross-sectional study in the islands of Lake Victoria (Lake Victoria Island Intervention Study on Worms 
and Allergy-related diseases [LaVIISWA] , shown in blue). B, Cumulative (EMaBS) and cross-sectional (LaVIISWA) seroprevalence of a pool of HuNoVs in children between 1 
and 5 years old. Error bars indicated 95% confidence limits.
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2 loci. We found that Se− individuals had similar distributions 
of GI.2 specific antibodies irrespective of ABO status and the 
protective B type effect was only observed in Se+ individuals 
(Pinteraction = 5.3 × 10−4) (Figure 4), as reported in outbreak stud-
ies cohorts [29].
Given the high seroprevalence of HuNoV in the Ugandan 
population, we used the clinical data available within EMaBS to 
determine the impact of FUT2 and ABO variation on episodes 
of diarrhea during early childhood. We identified a significantly 
lower rate of doctor-diagnosed diarrhea in Se− participants 
<1 year old (hazard ratio 0.89; 95% CI, 0.79–1.00); however, the 
difference was not sustained to age 5 years. There was statistical 
evidence for a difference in the association between the 2 age 
groups (P = .008; Table 3). We observed no effect on episodes 
of diarrhea at the ABO locus (Table 3), and the P value for the 
interaction between age and genotype was 0.77.
DISCUSSION
Our findings of high seroprevalence in 1-year-old children in 
the 2 cohorts of Ugandan children exceeds that reported for the 
same age group from several European countries (for exam-
ple, 47.3% in Finland, 42.7% in The Netherlands), but becomes 
comparable by 5  years old [30–32], suggesting greater risk of 
infection during infancy in Uganda. These findings are consist-
ent with the high incidence reported by RT-PCR–based fecal 
detection of HuNoVs in community birth cohort studies from 
India, Ecuador, Peru, and the multicentre MAL-ED study [6, 
20, 33, 34]. Such high infection rates may not be captured by 
incidence reporting in health care settings [7]. Taken as a whole, 
these community-based studies paint a picture of widespread 
HuNoV infections occurring early in life in low- and mid-
dle-income countries, where children are particularly vulner-
able to diarrheal diseases. This suggests that implementation of 
any future vaccination schedules would need to begin early in 
life, such as through a birth dose and/or early infant schedule, 
as per the World Health Organization Expanded Program on 
Immunization schedule that already exists for routine vacci-
nations in low-income settings. An effective HuNoV vaccine 
would also need to confer broad-range protection across geno-
types, as is evident from the high percentage of individuals with 
responses to multiple genotypes by age 2 years.
The seroprevalence was higher in 1-year-old children in the 
LaVIISWA survey of remote island-shore fishing villages than 
in the EMaBS cohort. It is possible that this reflects the nature 
of cross-sectional sampling in LaVIISWA, where those classi-
fied as 1 year olds could be closer to age 2, in comparison to the 
Table  1. Association Between Human Norovirus (HuNoV) Antibody 
Levels (OD450 Values) and Sociodemographic Factors Among 797 1-Year-
Old Children From the Entebbe Mother and Baby Study Cohort
Factor
Crude GMRs and P Values Adjusted GMRs and P Values
GMRa P Value GMRa P Value
Sex
Male
Female 0.99 (0.94–1.04) .67 0.99 (0.94–1.05) .78
Locationb
Urban
Periurban 1.06 (1.00–1.13) .04 1.08 (1.01–1.14)
Rural 1.09 (1.01–1.17) 1.10 (1.02–1.19) .02
Mother’s occupationc
Group 1
Group2 1.00 (0.93–1.07) .22 1.01 (0.94–1.09) .19
Group 3 0.94 (0.86–1.03) 0.95 (0.87–1.04)
Household SESd
1
2
3
4
5
6 1.00 (0.98–1.02) .99 (trend) 1.00 (0.98–1.02) .99 (trend)
HIV
Exposed
Unexposed 0.94 (0.85–1.03) .14 0.93 (0.85–1.02) .13
Diarrhea events
0
1–2 1.05 (0.99–1.12) 0.12 1.05 (0.99–1.12)
>2 1.00 (0.92–1.07) 1.00 (0.92–1.07) .14
All factors were adjusted for each other. Results obtained using linear regression of log10 
HuNoV antibody levels and back-transforming to obtain GMRs. 
Abbreviation: GMR, geometric mean ratio. 
aValues in parentheses indicate bootstrapped 95% confidence intervals. 
bUrban is Entebbe; periurban is Kigungu and Manyago; and rural is Katabi. 
cGroup  1 (farmer/fishing, unskilled manual, and bar/hotel); Group  2 (housewife); and 
Group 3 (business, student, professional). 
dSES, household socioeconomic status, 1– 6 (low–high). The GMR for household SES is for 
each unit increase in SES.
Table  2. Association Between Human Norovirus Antibody Levels and 
Sociodemographic Factors Among 375 Children From the Lake Victoria 
Island Intervention Study on Worms and Allergy-Related Diseases Survey
Factor
Crude GMRs and P Values Adjusted GMRs and P Values
GMRa P Value GMRa P Value
Sex
Male
Female 1.05 (0.98–1.14) .17 1.08 (0.99–1.16) .08
Age
1
2
3
4
5 1.05 (1.03–1.07) <.0001 (trend) 1.05 (1.03–1.08) <.0001 (trend)
Child’s school status
Student
Stay at 
home
1.09 (1.03–1.19) .04 1.00 (0.92–1.08) .93
All factors were adjusted for each other. Results obtained using linear regression analyses 
using the “svy” survey commands in Stata to allow for clustering of respondents within 
villages using linearized standard errors and for variable village sizes using weights. 
Abbreviation: GMR, geometric mean ratio. 
aValues in parentheses indicate bootstrapped 95% confidence intervals.
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EMaBS where the samples are taken close to each child’s birth-
day. However the increased seroprevalence was also expected 
given the lower standards of living in the island communities, 
including reduced access to proper sanitation and running 
water [18]. This is in line with our finding that 1-year-old chil-
dren in rural regions of the EMaBS catchment area had signifi-
cantly higher antibody levels to the pool of HuNoVs than those 
in urban areas, suggesting they have a greater chance of recur-
rent infection.
In estimating the cumulative seroprevalence for the EMaBS 
longitudinal birth cohort, we had to make a number of assump-
tions, whilst minimizing the potential of these to lead to over-
estimation. Firstly, we assumed that samples were missing from 
the database at random and that the rate of seroconversion for 
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Figure 2. Human genotype analysis of the relationship between human norovirus (HuNoV) antibody levels and α(1,2) fucosyltransferase 2 (FUT2) secretor status and or 
histo-blood group antigens (HBGA) type. A, Seroprevalence of different HuNoV genotypes in 2-year-old participants in the Entebbe Mother and Baby Study. B, Association 
between FUT2 secretor status and genotype-specific antibody levels. C, Association between HBGA type and genotype-specific antibody levels. ** P < .01; *** P < .001; NS, 
nonsignificant.
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these would be the same as for those which were available in 
that age group. This would not hold true if the children had 
different genetic or social risk factors; however, there were no 
differences in the recorded characteristics for individuals whose 
samples were present or missing. Secondly, we assumed that 
once a child had seroconverted they would remain seropositive. 
This was based on the results of a pilot screen in which we tested 
consecutive yearly samples from EMaBS participants and found 
that antibody levels to the pool of HuNoVs remained high each 
year after seroconversion (Supplementary Figure 1). In support 
of this, we found that higher antibody levels were significantly 
associated with increasing age in the LaVIISWA cross-sectional 
survey, indicative of repeat infections that may boost antibody 
titers. Additional studies are required to determine whether the 
IgG responses measured here are protective and capable of neu-
tralizing infection, which could now be tested using the recently 
developed cell culture systems for HuNoVs [14, 15]. Mucosal 
IgA has also recently been strongly correlated with protection 
in human volunteer challenge studies [35] and so inclusion of 
fecal or salivary IgA responses in any future serological studies 
will be essential to further understand the duration of protec-
tive immune responses.
Surprisingly, considering GII.4 global dominance [36], the 
seroprevalence of the GII.4 virus was comparable to the gen-
otype GI.1 Norwalk virus. GII.4 antibody levels were, however, 
significantly higher than for all other genotypes (Figure 3), sug-
gesting either repeat GII.4 infections that boost intragenotype 
responses, or that the GII.4 virus is more immunogenic, which 
could be linked to prolonged infections reported for some GII.4 
viruses compared to GI viruses [20]. Se− individuals have been 
shown to be resistant to infection by GI.1 Norwalk virus [37], 
yet the percentage seropositive for GI.1 exceeded the percent-
age of Se− individuals in the EMaBS cohort and Se− individu-
als did not have significantly lower antibody levels to Norwalk 
virus. As sensitivity to FUT2 status and HBGA expression can 
vary between strains [13], it is possible that we are measuring 
intragenotype responses to a related GI.1 virus, which may be 
able to infect Se− individuals. Previous volunteer studies have 
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Figure 3. Seropositivity to different human norovirus (HuNoV) genotypes in the 2-year-old age group of a longitudinal clinical cohort of Ugandan children (Entebbe Mother 
and Baby Study). A, The results are represented as a heat map, where each column represents a single sample and are ordered based on GI.1 responses from high to low. 
Colors indicate the relative OD450 value for each sample against each genotype. B, Comparison of the relative OD450 values for each genotype. Boxplot was generated with 
the Tukey method. Statistically significant differences were analyzed by 1-way ANOVA, using a Dunn multiple comparison test to compare all responses to the highest, GII.4. 
**** P < .0001.
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also reported a detectable IgG response against Norwalk virus 
in 78% of Se− individuals, who were otherwise protected from 
symptomatic infection [37]. Although GI viruses are thought to 
circulate at low levels worldwide [38], the seroprevalence of GI 
viruses in some African countries is higher than the global aver-
age [9], in line with our serology data. Multiple GI strains have 
been detected in surface water and sewage in different African 
countries [9]. Taken altogether, this suggests that GI viruses are 
endemic in Uganda and unsampled in the community, and that 
local circulation patterns exist, which may not reflect the global 
circulation of all strains.
The finding that nearly all seropositive 2  year olds display 
multiple genotype-specific serological responses, indicates the 
occurrence of repeat infections and the circulation of diverse 
HuNoV genotypes, as reported elsewhere [8, 23]. Importantly, 
the possibility of cross-reactive antibody responses, particularly 
between genotypes of the same genogroup, such as GII.4 and 
GII.6, cannot be excluded. However, we observed all combina-
tions of genotype responses, strongly supporting assay specific-
ity, and limited cross-reactivity has been reported for children 
<5  years old [39]. Furthermore, the genotypes used here have 
all recently been proposed to fall into different “immunotypes,” 
Table 3. Association Between (1,2) Fucosyltransferase 2 (FUT2) Secretor Status and ABO Phenotypic Blood Group and Diarrhea in 0 to 5-Year-Old Children
Age Group Genotype Person-Years (× 100) Number of Diarrhea Events Rate per 100 person-years Hazard Ratio (95% CI)  P value
 Secretor versus nonsecretor (rs601338)
<1 year Secretor (AG or GG) 10.9 1657 152.6 1
Nonsecretor (AA) 3.1 412 135.1 0.89 (0.79–1.00)
1–5 years Secretor (AG or GG) 39.6 1877 47.4 1 .21
Nonsecretor (AA) 11.3 581 51.5 1.09 (0.95–1.25)
 ABO blood group (rs8176747, rs8176719)
<1 year O 7.2 1083 151.3 1 .89
A 3.6 525 144.2 0.95 (0.84–1.08)
AB 0.4 65 144.4 0.95 (0.73–1.24)
B 2.7 396 148.9 0.98 (0.87–1.11)
1–5 years O 26.3 1289 49.1 1 .77
A 13.3 639 47.9 0.97 (0.86–1.10)
AB 1.6 84 52.8 1.07 (0.76–1.49)
B 9.7 446 46.0 0.93 (0.80–1.09)
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Figure 4. Relationship between α(1,2) fucosyltransferase 2 (FUT2) secretor status, histo-blood group antigens (HBGA) type, and GI.2-specific antibodies. Significance 
values are provided for tests of differences between distributions in individuals of O or B HGBA type, stratified by secretor status. The final significance value testing for 
interaction between secretor status and O/B HGBA type is also shown. Distributions of A and AB HGBA type individuals are provided for comparison although not included 
in the final interaction model. *** P < .001; NS, nonsignificant.
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reducing the likelihood of cross-reactive responses [23]. Several 
African case-control studies have described relatively high detec-
tion rates of HuNoV secretion in healthy controls [9]. It remains 
unclear whether this is due to asymptomatic infection or recent 
resolution of symptomatic infection; however, these studies sug-
gest that the appearance of symptoms may vary with genotype, 
host susceptibility (potentially Se status), and acquired immu-
nity. Further incidence studies are therefore required to confirm 
which circulating genotypes cause the most substantial disease 
in Uganda and how this links to Se status in this population.
In the context of numerous reports of incidence in health care 
settings [8–10], this dataset provides essential insight into the 
high community prevalence of HuNoVs in children in sub-Sa-
haran Africa and suggests that HuNoV infections are ubiqui-
tous, recurrent, occur within the first year of life, and may be 
a substantial cause of endemic childhood diarrhea in Uganda. 
Other birth cohort studies have shown that multiple symp-
tomatic HuNoV infections at an early age are associated with 
growth stunting [20]. This raises concerns as to whether the 
commonality of multiple HuNoV infections could be impact-
ing the growth and development of young Ugandan children 
and further studies will also be important to address this. Our 
data support the need for public health interventions coupled 
with routine HuNoV surveillance and molecular diagnostics 
across Africa, the latter of which could be achieved by expan-
sion of the African Rotavirus Surveillance Network to include 
HuNoVs. This is particularly important given the high preva-
lence of unsampled community HuNoV infections suggests 
that emergence of novel variants in Africa is likely.
Supplementary Data
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